HomeCompareCHDRF vs ABBV

CHDRF vs ABBV: Dividend Comparison 2026

CHDRF yields 2.98% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHDRF wins by $402.11M in total portfolio value· pulled ahead in Year 3
10 years
CHDRF
CHDRF
● Live price
2.98%
Share price
$568.00
Annual div
$16.93
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$402.21M
Annual income
$377,859,581.67
Full CHDRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CHDRF vs ABBV

📍 CHDRF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHDRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHDRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHDRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHDRF
Annual income on $10K today (after 15% tax)
$253.35/yr
After 10yr DRIP, annual income (after tax)
$321,180,644.42/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CHDRF beats the other by $321,159,588.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHDRF + ABBV for your $10,000?

CHDRF: 50%ABBV: 50%
100% ABBV50/50100% CHDRF
Portfolio after 10yr
$201.16M
Annual income
$188,942,176.71/yr
Blended yield
93.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHDRF
No analyst data
Altman Z
3.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHDRF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHDRFABBV
Forward yield2.98%3.06%
Annual dividend / share$16.93$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$402.21M$102.3K
Annual income after 10y$377,859,581.67$24,771.77
Total dividends collected$400.41M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHDRF vs ABBV ($10,000, DRIP)

YearCHDRF PortfolioCHDRF Income/yrABBV PortfolioABBV Income/yrGap
1$11,296$596.13$11,550$430.00$254.00ABBV
2$13,346$1,258.68$13,472$627.96$126.00ABBV
3← crossover$17,059$2,779.50$15,906$926.08+$1.2KCHDRF
4$24,894$6,641.05$19,071$1,382.55+$5.8KCHDRF
5$44,751$18,114.46$23,302$2,095.81+$21.4KCHDRF
6$108,750$60,866.33$29,150$3,237.93+$79.6KCHDRF
7$392,832$276,469.27$37,536$5,121.41+$355.3KCHDRF
8$2,287,008$1,866,677.30$50,079$8,338.38+$2.24MCHDRF
9$22,760,189$20,313,090.45$69,753$14,065.80+$22.69MCHDRF
10$402,212,984$377,859,581.67$102,337$24,771.77+$402.11MCHDRF

CHDRF vs ABBV: Complete Analysis 2026

CHDRFStock

Christian Dior SE, through its subsidiaries, engages in the production, distribution, and retail of fashion and leather goods, wines and spirits, perfumes and cosmetics, and watches and jewelry worldwide. The company offers its fashion and leather goods under the Louis Vuitton, Christian Dior Couture, Loewe, Marc Jacobs, Celine, Kenzo, Givenchy, Pink Shirtmaker, Emilio Pucci, Berluti, Loro Piana, Rimowa brand names; wines and spirits under the Hennessy, Glenmorangie, Ardbeg, a Belvedere, Volcán de mi Tierra, Moët & Chandon, Dom Pérignon, Veuve Clicquot, Krug, Château d'Yquem, Ruinart, Belvedere, Glenmorangie, Newton Vineyards, Bodega Numanthia, and Château d'Esclans brand names; and perfumes and cosmetics under the Parfums Christian Dior, Guerlain, Parfums Givenchy, Make Up For Ever, Benefit Cosmetics, Fresh, Acqua di Parma, KVD Vegan Beauty, Fenty, Ole Henriksen, and Maison Francis Kurkdjian brand names. It also provides watches and jewelry under the Tiffany, Bvlgari, TAG Heuer, Zenith, Hublot, Chaumet, and Fred brand names. In addition, the company operates retail stores under the DFS Galleria, Sephora, Le Bon Marché, and Ile de Beauté names; publishes Le Parisien- Aujourd'hui en France, a daily newspaper; designs and builds yachts; and operates the Cova pastry shops. Further, it is involved in real estate activities under the La Samaritaine brand name; and hotel business. The company sells its products through store network, including e-commerce websites; and agents and distributors. As of December 31, 2021, it operated 5,556 stores. The company was incorporated in 1946 and is headquartered in Paris, France. Christian Dior SE was formerly a subsidiary of Semyrhamis SA.

Full CHDRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHDRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHDRF vs SCHDCHDRF vs JEPICHDRF vs OCHDRF vs KOCHDRF vs MAINCHDRF vs JNJCHDRF vs MRKCHDRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.